MitoQ improves vascular function in healthy older adults (Rossman et al., 2018)
Human RCT — functional endpoint
Record verify: verified against primary source
| Design | Randomized, double-blind, placebo-controlled crossover trial (functional/vascular) |
| N | 20 |
| Registry | NCT02597023 |
| DOI | 10.1161/HYPERTENSIONAHA.117.10787 |
| Citation status | doi verified via Crossref 2026-07-12 (Hypertension 2018;71(6):1056-1063, Rossman et al., 'Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults'); NCT02597023 confirmed in the article's Clinical Trial Registration statement. PMID is not confirmed; see identifier status. |
Identifiers: DOI verified; PMID not reported; trial registry id reported, not independently verified. Record-level verification and identifier-level status are separate: a record can be verified against its primary publication on one identifier while another is simply not confirmed. No identifier is fabricated, and none is left in a “pending” state.
Five-qualifier claim
| Species / population | 20 healthy older adults (60-79 y) with impaired endothelial function. |
| Exposure, route, schedule | Oral MitoQ 20 mg/day for 6 weeks. |
| Comparator / duration | Placebo-controlled, double-blind, randomized crossover. |
| Endpoint / numeric result | Brachial-artery flow-mediated dilation ~42% higher after MitoQ vs placebo; lower aortic stiffness (in those with elevated baseline) and lower plasma oxidised LDL. |
| What it did NOT establish | Small, short crossover with surrogate vascular endpoints — no clinical-outcome or lifespan evidence. |
Interventions
What this trial administered
These are the compounds this trial administered, nothing more. MitoiX does not rank products, name a best one, or suggest a dose — read the record above and the primary reference, then talk to a clinician.
- MitoQ (mitoquinone) — MitoQ (mitoquinone)
Studied form: MitoQ, 20 mg/day for 6 weeks
Find MitoQ (mitoquinone) on Amazon →
Links marked with an arrow are affiliate links: MitoiX may earn a commission if you buy through them, at no extra cost to you. This never affects what is published — see the affiliate disclosure.
Primary reference
https://doi.org/10.1161/HYPERTENSIONAHA.117.10787
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status names the source and the date. An identifier that is not confirmed is named as such in the identifier row above, never filled in from a secondary source.